Qiagen Aug 9, 2021 Qiagen, OncXerna Therapeutics Ink Companion Dx Development, Technology-Licensing Deal Jul 1, 2021 Qiagen, Sysmex Form Global Companion Diagnostic Development Pact Jun 4, 2021 In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics May 28, 2021 FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen Feb 24, 2021 Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy Feb 18, 2021 Qiagen, Exosome Dx Building Urine-Based Digital PCR Workflow for FGFR Mutations in Bladder Cancer Premium Jan 13, 2021 PGDx, Qiagen Partner on Clinical Decision Support for Molecular Cancer Testing Nov 18, 2020 Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment Nov 17, 2020 Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition Feb 3, 2020 Qiagen Obtains CE Mark for PIK3CA Mutation Assay Jan 14, 2020 Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug Jun 18, 2019 Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program May 24, 2019 FDA Approves Novartis' Piqray for PIK3CA-Mutated Advanced Breast Cancer May 16, 2019 Qiagen, Inovio to Develop CDx for Immunotherapy Targeting Precancerous Cervical Lesions May 16, 2019 Novartis Seeks FDA OK for Drug With Favorable Phase III Results in PIK3CA-Mutated Breast Cancer Apr 12, 2019 FDA Approves Qiagen Companion Dx for Bladder Cancer Drug Balversa Jan 16, 2019 Qiagen EGFR Assay Approved in Japan as CDx to Pfizer NSCLC Drug Dec 19, 2018 FDA CDx Class Labeling Draft Guidance May Ease Patient Access, Spur Competition Among Test Makers Premium Dec 7, 2018 Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Sep 28, 2018 FDA Approves Expanded Use of Qiagen EGFR CDx in Lung Cancer Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
